Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Covance 4Q09 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Covance 4Q09

Early-Stage down, Late-Stage up

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Covance 4Q09

4Q Revenues: $485.1 million (+11%)

4Q Earnings: $41.5 million (-9%)

FY Revenues: $1.9 billion (+8%)

FY Earnings: $175.9 million (-11%)

Comments: Early Development revenues were down 5% to $203.1 million in 4Q09 and down 6% to $844.8 million in FY09, due to reduced demand. Toxicologu revenues were up for the second consecutive quarter, but Covance did not provide numbers for that subsegment. Late-Stage Development revenues were up 26% to $281.9 million in 4Q09 and up 22% to $1.1 billion in FY09. The company credited the performance of its central laboratory and clinical development units.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters